News | January 01, 2025
Anthem Biosciences files DRHP for Rs. 3,395 crore IPO
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Aims to achieve CDMO sales of US$ 400 million by 2028
Subscribe To Our Newsletter & Stay Updated
